Addressing Immune Checkpoint Resistance in Glioma with Dual-Siglec Inhibition

Research unit

INNOSUISSE

Project number

124.137 IP-LS

Project title

Addressing Immune Checkpoint Resistance in Glioma with Dual-Siglec Inhibition

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Glioblastomas are aggressive brain tumors currently not amenable to checkpoint inhibitor therapy. Our dual acting inhibitors aim to overcome immune suppression thus restoring or inducing anti-tumor immunity and improving patient outcomes.